DBV Technologies

The lead asset is Viaskin Peanut, a coin-sized epicutaneous patch that delivers microgram doses of peanut protein through intact skin. It targets desensitization in peanut-allergic children by training the immune system without the allergen entering the bloodstream, a delivery mechanism distinct from oral or injected immunotherapy. The firm's platform technology, Viaskin, is also being explored for milk and egg allergies, though all resources are currently concentrated on the peanut indication.

In 2020, the FDA issued a complete response letter for the original Biologics License Application, citing insufficient data on patch adherence and the need for a modified pivotal trial design. The agency did not raise safety concerns, but questioned whether the Phase 3 PEPITES study in 4-to-11-year-olds adequately demonstrated efficacy when controlling for application consistency. DBV spent the subsequent years redesigning the study to focus on a narrower age range and incorporating feedback on wear-time requirements.

VITESSE is the pivotal Phase 3 trial evaluating Viaskin Peanut in children aged 4–7. Enrollment was completed in September 2023, per the firm's official communications. The trial's primary endpoint measures the proportion of subjects who can tolerate a defined challenge dose of peanut protein after 12 months of treatment. Top-line data is generally anticipated 12–18 months from full enrollment, placing the critical readout window in late 2024 or early 2025.

DBV is a publicly traded biotech listed on Euronext Paris and NASDAQ, and it funds operations entirely through equity raises and cash conservation measures. It does not generate product revenue and has no pharmaceutical partnership revenue. The firm has conducted multiple restructurings — including facility closures and headcount reductions — to extend its cash runway through the VITESSE data readout.

No. Viaskin Peanut is investigational and not approved in any jurisdiction. The firm has no other commercial products, licensing deals, or contract manufacturing revenue. Its entire enterprise value rests on the clinical and regulatory success of a single drug-device combination.

The firm is headquartered in Montrouge, France, with a U.S. operational base in New York, New York. Its clinical programs are global, but its regulatory strategy is principally focused on the U.S. FDA and, secondarily, the European Medicines Agency. Manufacturing is managed internally for the patch device.

CEO Daniel Tassé has led the company since 2018, steering the regulatory resubmission strategy and the design of the VITESSE trial. He succeeded co-founder Pierre-Henri Benhamou, who transitioned from CEO to a board role. The narrow, binary nature of the asset means the CEO, alongside the board, directly controls the timing of capital raises, trial-data disclosures, and any potential partnering or M&A discussions.